Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies.

ABSTRACT:

Background

Chimeric antigen receptor (CAR) T-cell therapies are highly efficacious for several different hematologic cancers. However, for most CAR T targets it is observed that low surface antigen density on tumors can significantly reduce therapeutic efficacy. Here, we explore this dynamic in the context of CD72, a surface antigen we recently found as a promising target for refractory B-cell cancers, but for which CD72 low antigen density can lead to therapeutic resistance in preclinical models.

Methods

Primary samples were accessed via institutional review board-approved protocols. Affinity-matured and humanized nanobody clones were previously described in Temple et al.¹ CAR T-cells were generated via lentiviral transduction. In vitro cytotoxicity assays

SUBMITTER: Izgutdina A 

PROVIDER: S-EPMC12132434 | biostudies-literature | 2025 May

REPOSITORIES: biostudies-literature